Artivion, Inc. (NYSE:AORT) Given Average Rating of “Moderate Buy” by Analysts

Artivion, Inc. (NYSE:AORT) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $50.4667.

A number of research analysts recently issued reports on AORT shares. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Canaccord Genuity Group dropped their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Needham & Company LLC restated a “buy” rating and set a $58.00 target price on shares of Artivion in a report on Monday, February 2nd. Finally, Stifel Nicolaus set a $55.00 price target on shares of Artivion in a report on Thursday, March 5th.

Artivion Trading Down 6.7%

NYSE:AORT opened at $34.15 on Friday. The firm has a market capitalization of $1.64 billion, a P/E ratio of 170.78 and a beta of 1.63. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The company has a fifty day moving average of $38.08 and a 200 day moving average of $41.95. Artivion has a 52 week low of $21.97 and a 52 week high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The business had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, research analysts predict that Artivion will post 0.37 earnings per share for the current year.

Insider Activity at Artivion

In related news, CEO James P. Mackin sold 20,962 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $37.59, for a total value of $787,961.58. Following the completion of the transaction, the chief executive officer directly owned 780,031 shares of the company’s stock, valued at $29,321,365.29. This represents a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Jean F. Holloway sold 8,962 shares of Artivion stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $38.00, for a total value of $340,556.00. Following the sale, the senior vice president directly owned 185,095 shares in the company, valued at approximately $7,033,610. The trade was a 4.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 133,043 shares of company stock worth $4,977,158 over the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Artivion

Hedge funds have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd lifted its position in Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after buying an additional 519 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Artivion in the 3rd quarter worth about $27,000. Rockefeller Capital Management L.P. increased its stake in shares of Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after acquiring an additional 399 shares in the last quarter. Larson Financial Group LLC lifted its position in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after acquiring an additional 563 shares during the period. Finally, USA Financial Formulas lifted its position in Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after acquiring an additional 703 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.